E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the impact of a treat to target treatment follow up by e-Monitoring and fecal calprotectin dosing at home associated to an appropriate patient education versus standard treatment follow up at W48 in patients requiring a treatment with adalimumab (Humira®). |
|
E.2.2 | Secondary objectives of the trial |
score >1, and a Mayo endoscopy sub score of 0 or 1) • Remission without steroids • Endoscopic healing rate with Mayo score 0 or 1 • UCEIS score • Histological healing (Nancy score) • Remission rate and remission rate without steroids at study visits and W48 • Quality of life evolution • Disability score evolution • Patients satisfaction • Continuous response • Safety and tolerability • Anti-TNF pharmacokinetics • Number of visits in trial • Number of UC related hospitalizations • Number of colectomies • Treatment compliance (questionnaire) • Patient adhesion (questionnaire) • Medico-economic analysis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Adults with moderately-to-severely active Ulcerative Colitis (UC) who had an inadequate response to or failed to tolerate steroids and thiopurines (azathioprine or 6-mercaptopurine) or methotrexate or adults with moderately-to-severely active UC who had no response to an adequate steroid course - Age ≥ 18 years and < 75 years - Patients scheduled to start a treatment with adalimumab - Naïve to anti-TNF therapy and other biologics (i.e anti-integrin antibodies) or other biologics known to be effective for UC (approved or investigational) - Naïve to JAK inhibitors (approved or investigational) - moderately-to-severely active UC for at least 3 months with a Mayo score of 6-12 points (endoscopy subscore of at least 2) - Established diagnosis of UC for at least 3 months (pancolitis, left-sided colitis, proctosigmoiditis and proctitis are allowed). - Patient has to be treated with oral 5-ASA at time of inclusion regardless of the dose if no contra-indication. - Azathioprine, 6-mercaptopurine or methotrexate will be stopped two weeks before inclusion. - A contraceptive method during the whole trial for childbearing potential female - Patient familiar with Smartphone and internet use
|
|
E.4 | Principal exclusion criteria |
- Patients unable to give their consent (because of their physical or mental state). - Absence of written consent. - Pregnancy or breastfeeding. - Patients with severe acute colitis or patients at imminent risk for colectomy. - History of colectomy. - History of colonic mucosal dysplasia or adenomatous colonic polyps that are not removed. - Screening stool trial positive for enteric pathogens or Clostridium difficile toxin. - Oral corticosteroids at a dose > 40 mg prednisone or its equivalent per day at inclusion (oral steroids should be at stable dose at least 7 days before inclusion) - Any current or previous use of cyclosporine, tacrolimus, anti-TNF therapy, and other biologics, including anti-integrin antibodies (approved or investigational), JAK inhibitors (approved or investigational), or any current or previous use of an investigational agent within 5 half-lives of that agent before the first trial agent injection. - Contraindication to anti-TNF therapy according to drug labeling: o Active infection. o Non-treated latent tuberculosis. o Heart failure (NYHA: Grade III and IV). o Malignancy during the previous 5 years. o Demyelinating neurological disease. o Current or recent (less than 4 weeks) vaccination with attenuated live vaccines - Patients with a dominant arm deficiency or physical impairment impeding the achievement of the tests - Patients using a prohibited medication - Patients participating in another trial or being in a follow-up period for another trial |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Treatment success of a treat to target with telemonitoring follow up using e-Monitoring and fecal calprotectin dosing at home associated to an appropriate patient education compared to standard treatment follow up at W48. Definition of treatment success: Endoscopic remission defined by an endoscopic Mayo score 0
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Clinical remission (Clinical remission is defined as a total Mayo score ≤2 points, with no individual sub score >1, and a Mayo endoscopy sub score of 0 or 1) - Remission without steroids - Endoscopic healing rate with Mayo score 0 or 1 - UCEIS score - Histological healing (Nancy score) - Remission rate and remission rate without steroids at study visits and W48 - Quality of life evolution (evaluate visit 0 vs W14, W26, W38 and W48) - Patients satisfaction - Continuous response - Safety and tolerability - Anti-TNF pharmacokinetics - Number of visits in trial - Number of UC related hospitalizations - Number of colectomies - Treatment compliance (questionnaire) - Patient adhesion (questionnaire) - Medico-economic analysis |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Therapeutic strategy: Comparing standard of care VS treat to target with telemonitoring |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |